These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 15598707

  • 1. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 2. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 3. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis.
    Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR, Genovese M, Sundaramurthy S, Schiff M.
    Arthritis Rheum; 2004 Apr 15; 51(2):228-32. PubMed ID: 15077264
    [Abstract] [Full Text] [Related]

  • 4. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
    Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Loet XL, Cantagrel A, Pavy S, Deslandre CJ, Debiais F, Combe B, Club Rheumatismes et Inflammation.
    J Rheumatol; 2006 May 15; 33(5):865-9. PubMed ID: 16652418
    [Abstract] [Full Text] [Related]

  • 5. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P.
    J Rheumatol; 2004 Oct 15; 31(10):1906-11. PubMed ID: 15468352
    [Abstract] [Full Text] [Related]

  • 6. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Peterson AN, Doyle J, Huse DM.
    Am J Manag Care; 2002 May 15; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [Abstract] [Full Text] [Related]

  • 7. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F, Michaud K, Stephenson B, Doyle J.
    J Rheumatol; 2003 Aug 15; 30(8):1725-32. PubMed ID: 12913927
    [Abstract] [Full Text] [Related]

  • 8. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B, Breedveld F.
    Arthritis Rheum; 2003 Jun 15; 48(6):1513-20. PubMed ID: 12794818
    [Abstract] [Full Text] [Related]

  • 10. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 15; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 11. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J.
    Ann Rheum Dis; 2009 Aug 15; 68(8):1285-9. PubMed ID: 19351624
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.
    Semin Arthritis Rheum; 2011 Dec 15; 41(3):401-5. PubMed ID: 21862107
    [Abstract] [Full Text] [Related]

  • 13. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
    Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N.
    J Rheumatol; 2006 Mar 15; 33(3):486-9. PubMed ID: 16511917
    [Abstract] [Full Text] [Related]

  • 14. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr 15; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 15. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R, European Leflunomide Study Group.
    J Rheumatol; 2001 Sep 15; 28(9):1983-91. PubMed ID: 11550964
    [Abstract] [Full Text] [Related]

  • 16. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P.
    Ann Rheum Dis; 2005 Jan 15; 64(1):44-51. PubMed ID: 15271770
    [Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C.
    Arthritis Rheum; 2002 Dec 15; 47(6):655-61. PubMed ID: 12522841
    [Abstract] [Full Text] [Related]

  • 18. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan 15; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J.
    Arthritis Rheum; 2003 Aug 15; 48(8):2224-33. PubMed ID: 12905476
    [Abstract] [Full Text] [Related]

  • 20. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 15; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.